Mylan, U.S. finalize $465 million EpiPen settlement

Reuters News
Posted: Aug 17, 2017 10:35 AM

BOSTON (Reuters) - Mylan NV has finalized a $465 million settlement with the U.S. Justice Department resolving claims it overcharged the government for its EpiPen emergency allergy treatment, which became the center of a firestorm over price increases.

The U.S. Attorney's Office in Massachusetts revealed the accord on Thursday, 10 months after Mylan said it reached a deal resolving claims it misclassified the EpiPen as a generic rather than a branded product, underpaying rebates to the Medicaid program as a result.

(Reporting by Nate Raymond in Boston; Editing by Nick Zieminski)